Search Videos by Topic or Participant
Browse by Series:

mTOR Inhibition for Poor-Risk RCC

Insights From: Prof. Bernard Escudier, MD, Institute Gustave Roussy; Susanne Osanto, MD, PhD, Leiden University Medical Center
Published: Monday, Feb 15, 2016


Treatment can be tailored for patients with poor risk metastatic renal cell carcinoma based on whether they have a poor or a good performance status, notes Bernard Escudier, MD. For those with poor performance status, Escudier prefers temsirolimus. For patients with a good performance status, he prefers to use a tyrosine kinase inhibitor (TKI) in frontline setting.

In the absence of head-to-head studies, a question that often arises, is whether temsirolimus and everolimus are interchangeable. The side effects differ, and the kinetics are different, says Susanne Osanto, MD. Although most of the data in this group of patients are with temsirolimus, in daily practice, many poor-risk patients will receive everolimus. Some will receive upfront TKIs, she adds. Upon progression, patients may be switched to an alternate class of drugs.

If a patient has several bone metastases, systemic treatment will be needed, states Osanto. If a patient has one or two bone metastases, irradiation may be appropriate. TKI therapy can be resumed following irradiation, she adds. Patients with multiple brain metastases have a poor prognosis, and there are not a lot of data in this population, says Escudier. Stereotactic radiotherapy is feasible, if a patient has up to five brain metastases. Another option to consider for these patients is neurosurgery followed by irradiation.
Slider Left
Slider Right


Treatment can be tailored for patients with poor risk metastatic renal cell carcinoma based on whether they have a poor or a good performance status, notes Bernard Escudier, MD. For those with poor performance status, Escudier prefers temsirolimus. For patients with a good performance status, he prefers to use a tyrosine kinase inhibitor (TKI) in frontline setting.

In the absence of head-to-head studies, a question that often arises, is whether temsirolimus and everolimus are interchangeable. The side effects differ, and the kinetics are different, says Susanne Osanto, MD. Although most of the data in this group of patients are with temsirolimus, in daily practice, many poor-risk patients will receive everolimus. Some will receive upfront TKIs, she adds. Upon progression, patients may be switched to an alternate class of drugs.

If a patient has several bone metastases, systemic treatment will be needed, states Osanto. If a patient has one or two bone metastases, irradiation may be appropriate. TKI therapy can be resumed following irradiation, she adds. Patients with multiple brain metastases have a poor prognosis, and there are not a lot of data in this population, says Escudier. Stereotactic radiotherapy is feasible, if a patient has up to five brain metastases. Another option to consider for these patients is neurosurgery followed by irradiation.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x